Insider Selling: LifeStance Health Group (NASDAQ:LFST) COO Sells $215,252.84 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) COO Lisa Miller sold 14,663 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $14.68, for a total value of $215,252.84. Following the transaction, the chief operating officer owned 251,904 shares in the company, valued at $3,697,950.72. The trade was a 5.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

LifeStance Health Group Trading Down 0.5%

Shares of LFST stock traded down $0.07 during trading hours on Friday, hitting $14.08. 3,728,905 shares of the company were exchanged, compared to its average volume of 6,598,220. The company has a 50 day simple moving average of $12.79 and a two-hundred day simple moving average of $9.67. The firm has a market cap of $5.35 billion, a P/E ratio of 74.11 and a beta of 1.35. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.44 and a current ratio of 1.44. LifeStance Health Group, Inc. has a fifty-two week low of $6.01 and a fifty-two week high of $15.66.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $455.86 million for the quarter, compared to the consensus estimate of $431.59 million. LifeStance Health Group had a net margin of 4.29% and a return on equity of 4.82%. The company’s revenue was up 25.3% compared to the same quarter last year. Equities analysts anticipate that LifeStance Health Group, Inc. will post 0.18 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of LifeStance Health Group in the second quarter valued at $389,293,000. Marshall Wace LLP increased its position in shares of LifeStance Health Group by 511.8% during the third quarter. Marshall Wace LLP now owns 9,955,435 shares of the company’s stock worth $119,764,000 after acquiring an additional 8,328,169 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of LifeStance Health Group by 16.4% during the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock worth $66,038,000 after acquiring an additional 1,461,215 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after acquiring an additional 2,843,388 shares during the last quarter. Finally, Voya Investment Management LLC raised its holdings in shares of LifeStance Health Group by 1,249.6% in the 3rd quarter. Voya Investment Management LLC now owns 3,971,989 shares of the company’s stock worth $47,783,000 after acquiring an additional 3,677,679 shares during the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on LFST shares. Barclays lifted their price target on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, September 10th. Canaccord Genuity Group increased their price objective on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Wall Street Zen upgraded LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday. BTIG Research raised their target price on LifeStance Health Group from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Finally, KeyCorp raised their price objective on LifeStance Health Group from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.86.

About LifeStance Health Group

LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance’s clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.